University of Kentucky College of Agriculture, Food & Environment

 

Gluck Center > Directory > Gluck Faculty >Tobin, T > Curriculum Vitae

CURRICULUM VITAE

Thomas Tobin, MVB, MSc, PhD, MRCVS, DABT
ttobin@uky.edu
(859) 218-1092
Fax: (859) 257-8542
www.thomastobin.com

Professor
Department of Veterinary Science
M.H. Gluck Equine Research Center
College of Agriculture, Food & Environment
Professor
The Graduate Center for Toxicology
University of Kentucky

Education

MVB (DVM); University College, Dublin, 1964

MSc; Pharmacology, University of Guelph, 1966

PhD; Pharmacology-Toxicology, University of Toronto, 1970

Licenses

MRCVS – Member, Royal College of Veterinary Surgeons, 1964
Kentucky Veterinary Boards License, NS-1053

Board Certification

DABT-Diplomate, American Board of Toxicology, Inc. 1980-Date

Employment

Professor of Veterinary Science, Gluck Equine Research Center, U.K.

Professor, Graduate Center for Toxicology, U.K.

Intellectual Property

Patent for a morphine/drug detection technique, 1983. WTT, Inc., created with licenses for 50-plus ELISA tests, 1991. Sold to Neogen, Inc. as ELISA Technologies, 1993. Currently, 100 employees in Lexington, $30M sales, significant UK royalty. Thirty-plus unique equine drug metabolites and deuterated standards synthesized and licensed. Patent for treatment of EPM granted, licensed and marketed as Marquis®, August 2001, significant UK royalty. Other patents/ intellectual properties in progress. Unique mathematical analysis and biologically unique proposed pathogenesis of MRLS copyrighted (TXVIIII484). Publishing/other royalties.

Teaching

Toxicology, Pharmacology, “Ethics in Scientific Research,” “Risk Assessment,” International Short Courses: “The Commission Veterinarian/Equine Medical Director” 1995 to 2001, and “Testing for Therapeutic Medications, Dietary and Environmental Substances.” Six Kentucky Veterinarian’s Short Courses, 2000-2001. Bain-Fallon Lectures, Gold Coast, Australia, 2002. Workshop on Mare Reproductive Loss Syndrome (MRLS), August 2002, Published, May 2003.

Honors

HBPA Man of the Year, 1995; Kentucky HBPA Man of the Year, 1999; Toxicology Student Award, 1993; Toxicology rated the only “extremely effective” graduate program in Kentucky by National Research Council, 1992-93; Bain Fallon Lectures, 1990; The “Dr. Thomas Tobin Purse,” August 1, Emerald Downs, Seattle, Washington, 1999; Numerous advisory boards. Honorary faculty, College of Veterinary Medicine, Cordoba, Argentina, “Thomas Tobin Purse”, Cordoba, August, 2001. The Professor Thomas Tobin Trophy, Cayamanas Racetrack, Jamaica, April 20th, 2002. Bain-Fallon Lectures, Gold Coast, Australia, July 2002.

Research Support

Approximately $13 million through 2007.

Publications

About 400-papers, 100-plus abstracts, two books, five volumes of proceedings. Numerous articles published and reprinted in lay journals. See www.thomastobin.com for a full indexed listing of publications and presentations.

Drugs and the Performance Horse, by Thomas Tobin. Foreword by HRH, The Duke of Edinburgh. 480 pp., Springfield, Illinois: Charles C. Thomas, 1981.

Proceedings of the Workshop on Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horse. 218 pages, 1995.

Proceedings of the First Workshop on Mare Reproductive Loss Syndrome. 134 pages, 2002.

Biographical Sketch

Thomas Tobin (TT), Veterinarian, Dublin, 64, Pharmacologist MSc, Guelph, 66, PhD, Toronto, 70, faculty, Michigan State University, Equine Pharmacology, Therapeutics and Toxicology program at the University of Kentucky, 75-date. In 1979 organized the Third Int.Symp.on Equine Medication Control, in 1981 published Drugs and the Performance Horse, 500 page text. In 1983 testified before Congress on the “Corrupt Horse Racing Practices Act”; thereafter, activity on this bill ceased.

In 1980 became a Diplomate of the America Board of Toxicology. In 1985 he began research that introduced ELISA testing to horse racing. Licensing and commercialization of this technology led to the creation of WTT ELISA TESTS, later sold to Neogen Corp (www.neogen.com). Neogen Lexington now employs 100, brings in $30M/year and an ongoing significant royalty to UK.

In 1988 became Director of the UK Graduate Center for Toxicology, developed minority programs and brought in a $800K NIEHS Training Grant. By 93 core faculty and student admissions were up three-fold, extramural funding had increased from 0 to $800K per year, and courses on “Ethics in Scientific Research” and “Risk Assessment” had been developed. When NRC reviewed Kentucky doctoral programs in 93, only The Graduate Center for Toxicology was rated “extremely effective.”

In 1994, TT organized an international workshop, “Testing for Therapeutic Medications, Environmental and Dietary Substances in Racing Horses,” that brought 70 industry leaders to Lexington. In 1995, TT and colleagues organized “The Commission Veterinarian/Equine Medical Director: A Short Course”. In 1995, TT and colleagues founded the Testing Integrity Program (TIP) that serves as a national drug testing Quality Assurance Program. TT was named “Man of the Year” in 1995 by the National Horsemen's Benevolent and Protective Association.

In 1996, TT and David Granstrom investigated new therapeutic approaches to Equine Protozoal Myelitis (EPM) rapidly establishing the therapeutic efficacy of diclazuril and toltrazuril. A patent in this area was granted (#5,883,095, 1999) and licensed to Bayer Animal Health; in July 2001, Bayer Marquis® (toltrazuril sulfone www.yourhorseshealth.com/epm/treat.html), was the first FDA-approved treatment for EPM and brings in a significant royalty to UK.

In 1998 the industry became focused on clenbuterol. A series of LC-MS-MS based studies led to publication of a highly sensitive serum test for clenbuterol, allowing much more sensitive and reliable regulatory control of therapeutic medications than previously possible. In 1998 TT also organized and published a TIP seminar on furosemide.

In 2000, at the direction of the Kentucky Racing Commission (KRC), TT developed a series of nationally accredited continuing education short courses for veterinary practitioners and regulatory veterinarians in Kentucky and surrounding states. Six short courses were offered.

In May of 2001, TT chaired the Toxicology Working Group investigating the spring 2001 Mare Reproductive Loss Syndrome (MRLS), and his research group was temporarily redirected to work on MRLS. Within three weeks the Eastern Tent Caterpillar was identified as the most likely cause of MRLS. Work in spring 2002 clearly linked MRLS to the Eastern Tent Caterpillar; in August 2002, TT and David Powell organized the first workshop on the Mare Reproductive Loss Syndrome, published in May 2003. In 2003 LFL/MRLS was shown to follow an unusual probabilistic model, Accelerated Failure Time analysis, and a biologically unique pathogenesis for MRLS (www.jarvm.com/articles/Vol2Iss2/TOBINJARVMVol2No2.pdf) based on septic penetrating setal fragments was proposed.

In 2003 the program contributed to the writing of the National HBPA Proposed Policy on Drug Testing and Therapeutic Medication (http://hbpa.org/resources/MedicationPolicy.pdf) and has since focused on developing fully validated analytical methods for agents abused in racing horses. In June of 2003 it was decided that it would be in the best interests of the racing industry in Kentucky for the program to accredit, and the process of becoming A2LA accredited was initiated.

In 2004 the program was redirected to emphasize new therapeutics and toxicology, with an emphasis on equine diagnostics, prophylaxes and therapeutics. In 2005, the program began synthesizing series of deuterated internal standards for equine therapeutic medications; in July 2006, US Patent # 7,074,843 for a novel veterinary sedative and tranquilizer was awarded and a unique pathogenesis for oligofructan based laminitis was proposed.

 

Maxwell H.Gluck Equine Research Center
Department of Veterinary Science, University of Kentucky
Lexington, Kentucky 40546-0099

Main Office (859) 257-4757
Fax (859) 257-8542